#antibody-therapies

#antibody-therapies

Chronic inflammation is a central driver of pathological fibrosis after ischaemic or haemodynamic stress, but strategies that locally rebalance injurious and reparative immune responses without systemic immunosuppression are lacking.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.

The funds raised through Visionaries of the Year are used for research to advance lifesaving therapies like immunotherapy, genomics and personalized medicine, which are saving lives today.

When mitochondria are exposed to tissue or blood, they lose the electrical gradient across their outer membrane. Mitochondria that lack such a gradient are recognized by a cell's internal machinery as damaged and quickly destroyed. The vast majority of previous studies involved injecting 'naked' mitochondria directly into the bloodstream or tissue sites, but the approach isn't very efficient, so researchers often have to use 'ridiculous' doses of mitochondria.

X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.

On Tuesday the American Cancer Society (ACS) released its annual report on cancer statistics in the U.S., and it offered a rare bit of good news: the proportion of people who were alive at least five years after a cancer diagnosis hit a record high. The report found that, among all cancer patients diagnosed between 2015 and 2021 in the U.S., the survival rate at the five-year mark relative to those who didn't have cancer was 70 percent.

We knew that if you inject these nanoparticles into an animal model, the nanoparticles get taken up by antigen presenting cells and this resulted in increased regulatory T-cells and decreased inflammatory disease. However, we did not know how this happens,

More than 17,500 patients are living on the waiting list at any given time for a liver transplant. Unfortunately, there aren't enough of the available, donated organs to go around, leading to a critical and frequently deadly backlog. Roughly 10% of the patients on that waiting list die each year while waiting for the prospect of a new organ.

Now, researchers have created an artificial-intelligence system that vastly simplifies and accelerates the process of chemical synthesis. The system, which is called MOSAIC and is described in a study published in Nature on 19 January, recommended conditions that researchers were able to use to generate 35 compounds with the potential to become products like pharmaceuticals, agrochemicals or cosmetics without needing to do any further trawling or tweaking.

Before treatment began, participants underwent neuroimaging. Instead of relying on a single modality, the researchers fused structural connectivity (how regions are physically wired) with functional connectivity (how regions co-activate at rest). The goal was not to throw every possible feature at a black box, but to learn a constrained pattern-what the authors call structure-function "covariation"-that carries the most predictive signal for outcome. In other words, the model tries to find the smallest set of connections that meaningfully forecasts symptom change.

Although specific bacterial taxa have been associated with favourable clinical responses to immune checkpoint blockade (ICB) in cancer patients12,13,18,19,20,21,22, the mechanisms by which the intestinal microbiota influences anti-tumour immune responses remain poorly defined. Products of the microbiota, including metabolites23,24,25 and innate receptor ligands26, may reprogramme myeloid cells27, lowering the activation threshold for antigen presentation and thereby facilitating priming and activation of tumour-reactive T cells.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.

As for side effects, the companies reported that little had changed from previous analyses; adverse events were similar between the two groups. The top side effects linked to the vaccine were fatigue, injection site pain, and chills. The results "highlight the potential of a prolonged benefit" of the vaccine combined with Keytruda in patients with high-risk melanoma," Kyle Holen, a senior vice president at Moderna, said. They also "illustrate mRNA's potential in cancer care," he said, noting that the company has eight more Phase 2 and Phase 3 trials going for mRNA vaccines against a variety of other cancers, including lung, bladder, and kidney cancers.

EMPAVELI is the first and only approved treatment for C3G and IC-MPGN across pediatric patients 12+, adults, and post-transplant recurrence. That's roughly 5,000 patients in the U.S., with EMPAVELI holding exclusive approval for about two-thirds. Add the European CHMP positive opinion in December 2025, and you have a rare disease franchise with global expansion potential and pricing power that typically commands gross margins north of 90%.

Anais Muczynski, 36, an orthoptist who lives with her husband Vincent Muczynski, 41, a researcher, received her primary breast cancer diagnosis in January 2023 after discovering a quail egg-sized lump in her left breast. At the time, the London-based couple were "optimistic", as it was stage one meaning the cancer was only in the breast tissue or in the lymph nodes close to the breast and she underwent chemotherapy, immunotherapy, and a double mastectomy.